Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R.

J Immunother Cancer. 2018 Apr 4;6(1):24. doi: 10.1186/s40425-018-0334-x.

2.

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF.

Science. 2018 Mar 23;359(6382):1366-1370. doi: 10.1126/science.aar6918. Review.

PMID:
29567708
3.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Feb 13:JCO2017762229. doi: 10.1200/JCO.2017.76.2229. [Epub ahead of print]

PMID:
29437535
4.

Back from the dead: TIL apoptosis in cancer immune evasion.

Horton BL, Gajewski TF.

Br J Cancer. 2018 Feb 6;118(3):309-311. doi: 10.1038/bjc.2017.483. Epub 2018 Jan 23. No abstract available.

PMID:
29360810
5.

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.

Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W.

Exp Hematol Oncol. 2018 Jan 11;7:1. doi: 10.1186/s40164-018-0093-x. eCollection 2018.

6.

Impact of oncogenic pathways on evasion of antitumour immune responses.

Spranger S, Gajewski TF.

Nat Rev Cancer. 2018 Mar;18(3):139-147. doi: 10.1038/nrc.2017.117. Epub 2018 Jan 12. Review.

PMID:
29326431
7.

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF.

Science. 2018 Jan 5;359(6371):104-108. doi: 10.1126/science.aao3290.

PMID:
29302014
8.

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S.

Adv Exp Med Biol. 2017;1036:19-31. doi: 10.1007/978-3-319-67577-0_2.

PMID:
29275462
9.

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.

Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF.

Cancer Immunol Res. 2018 Jan;6(1):14-24. doi: 10.1158/2326-6066.CIR-17-0249. Epub 2017 Nov 2.

PMID:
29097422
10.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e15. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

PMID:
29033130
11.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.

Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.

PMID:
28886381
12.

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.

Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM.

Melanoma Res. 2017 Aug;27(4):342-350. doi: 10.1097/CMR.0000000000000353.

PMID:
28489678
13.

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Spranger S, Dai D, Horton B, Gajewski TF.

Cancer Cell. 2017 May 8;31(5):711-723.e4. doi: 10.1016/j.ccell.2017.04.003.

14.

The Microbiota: A New Variable Impacting Cancer Treatment Outcomes.

Fessler JL, Gajewski TF.

Clin Cancer Res. 2017 Jul 1;23(13):3229-3231. doi: 10.1158/1078-0432.CCR-17-0864. Epub 2017 Apr 26.

PMID:
28446507
15.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.

Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL Jr.

Oncoimmunology. 2016 Oct 18;5(12):e1240857. doi: 10.1080/2162402X.2016.1240857. eCollection 2016.

16.

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.

Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF.

J Exp Med. 2017 Feb;214(2):381-400. doi: 10.1084/jem.20160485. Epub 2017 Jan 23.

17.

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF.

Clin Cancer Res. 2017 Jul 1;23(13):3269-3276. doi: 10.1158/1078-0432.CCR-16-2272. Epub 2017 Jan 4.

PMID:
28053021
18.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.

Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19.

19.

Innate immune signaling and regulation in cancer immunotherapy.

Corrales L, Matson V, Flood B, Spranger S, Gajewski TF.

Cell Res. 2017 Jan;27(1):96-108. doi: 10.1038/cr.2016.149. Epub 2016 Dec 16. Review.

20.

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.

Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD.

J Cancer Res Clin Oncol. 2017 Mar;143(3):439-445. doi: 10.1007/s00432-016-2318-x. Epub 2016 Dec 5.

21.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

22.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

23.

Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. Epub 2016 Nov 11.

24.

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ.

J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016.

25.

Lymphatic vessels regulate immune microenvironments in human and murine melanoma.

Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, Alitalo K, Eikesdal HP, Wiig H, Swartz MA.

J Clin Invest. 2016 Sep 1;126(9):3389-402. doi: 10.1172/JCI79434. Epub 2016 Aug 15.

26.

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.

Mikucki ME, Skitzki JJ, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS.

Oncoimmunology. 2016 Feb 11;5(5):e1116675. doi: 10.1080/2162402X.2015.1116675. eCollection 2016 May.

27.

The host STING pathway at the interface of cancer and immunity.

Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF.

J Clin Invest. 2016 Jul 1;126(7):2404-11. doi: 10.1172/JCI86892. Epub 2016 Jul 1. Review.

28.

NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.

Iraolagoitia XL, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nuñez SY, Secchiari F, Gajewski TF, Zwirner NW, Fuertes MB.

J Immunol. 2016 Aug 1;197(3):953-61. doi: 10.4049/jimmunol.1502291. Epub 2016 Jun 24.

29.
30.

The composition of the microbiota modulates allograft rejection.

Lei YM, Chen L, Wang Y, Stefka AT, Molinero LL, Theriault B, Aquino-Michaels K, Sivan AS, Nagler CR, Gajewski TF, Chong AS, Bartman C, Alegre ML.

J Clin Invest. 2016 Jul 1;126(7):2736-44. doi: 10.1172/JCI85295. Epub 2016 Jun 20.

31.

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.

Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF.

Cancer Immunol Res. 2016 Jul;4(7):563-8. doi: 10.1158/2326-6066.CIR-15-0274. Epub 2016 May 17.

32.

Tumor-intrinsic oncogene pathways mediating immune avoidance.

Spranger S, Gajewski TF.

Oncoimmunology. 2015 Aug 31;5(3):e1086862. eCollection 2016 Mar. Review.

33.

MYC - a thorn in the side of cancer immunity.

Spranger S, Gajewski TF, Kline J.

Cell Res. 2016 Jun;26(6):639-40. doi: 10.1038/cr.2016.50. Epub 2016 Apr 26.

34.

Germ Warfare.

Alegre ML, Gajewski TF.

Sci Am. 2016 Apr;314(4):50. doi: 10.1038/scientificamerican0416-50. No abstract available.

PMID:
27082192
35.

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.

Corrales L, Woo SR, Williams JB, McWhirter SM, Dubensky TW Jr, Gajewski TF.

J Immunol. 2016 Apr 1;196(7):3191-8. doi: 10.4049/jimmunol.1502538. Epub 2016 Feb 29.

36.

Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Spranger S, Sivan A, Corrales L, Gajewski TF.

Adv Immunol. 2016;130:75-93. doi: 10.1016/bs.ai.2015.12.003. Epub 2016 Jan 22.

37.

Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection.

Evaristo C, Spranger S, Barnes SE, Miller ML, Molinero LL, Locke FL, Gajewski TF, Alegre ML.

J Immunol. 2016 Apr 1;196(7):2933-8. doi: 10.4049/jimmunol.1501144. Epub 2016 Feb 22.

38.

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P.

Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8.

39.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

40.

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF.

Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.

41.

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion.

Spranger S, Gajewski TF.

J Immunother Cancer. 2015 Sep 15;3:43. doi: 10.1186/s40425-015-0089-6. eCollection 2015.

42.

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.

Corrales L, Gajewski TF.

Clin Cancer Res. 2015 Nov 1;21(21):4774-9. doi: 10.1158/1078-0432.CCR-15-1362. Epub 2015 Sep 15. Review.

43.

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Gajewski TF.

Semin Oncol. 2015 Aug;42(4):663-71. doi: 10.1053/j.seminoncol.2015.05.011. Epub 2015 Jun 3. Review.

44.

Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.

Corrales L, Gajewski TF.

Cytokine. 2016 Jan;77:245-7. doi: 10.1016/j.cyto.2015.08.258. Epub 2015 Aug 24. No abstract available.

45.

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.

Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS.

Nat Commun. 2015 Jun 25;6:7458. doi: 10.1038/ncomms8458.

46.

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Spranger S, Bao R, Gajewski TF.

Nature. 2015 Jul 9;523(7559):231-5. doi: 10.1038/nature14404. Epub 2015 May 11.

PMID:
25970248
47.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF.

Cell Rep. 2015 May 19;11(7):1018-30. doi: 10.1016/j.celrep.2015.04.031. Epub 2015 May 7.

48.

The STING pathway and the T cell-inflamed tumor microenvironment.

Woo SR, Corrales L, Gajewski TF.

Trends Immunol. 2015 Apr;36(4):250-6. doi: 10.1016/j.it.2015.02.003. Epub 2015 Mar 7. Review.

49.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS.

Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18.

50.

T cell-NF-κB activation is required for tumor control in vivo.

Barnes SE, Wang Y, Chen L, Molinero LL, Gajewski TF, Evaristo C, Alegre ML.

J Immunother Cancer. 2015 Jan 20;3(1):1. doi: 10.1186/s40425-014-0045-x. eCollection 2015.

Supplemental Content

Loading ...
Support Center